Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Clinical Microbiology & Infectious Diseases
Published in: European Journal of Clinical Microbiology & Infectious Diseases 2/2005

01-02-2005 | Review

Low-level vancomycin resistance in Staphylococcus aureus—an Australian perspective

Authors: B. P. Howden, P. B. Ward, P. D. R. Johnson, P. G. P. Charles, M. L. Grayson

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 2/2005

Login to get access

Abstract

Low-level vancomycin resistance in Staphylococcus aureus has emerged as a clinical problem over the past 8 years. The clinical relevance of this resistance has been questioned, and laboratory detection remains difficult and time consuming. There is, however, increasing evidence linking low-level vancomycin resistance with glycopeptide treatment failure in serious Staphylococcus aureus infections. Diagnostic laboratories and clinicians need to be aware of this resistance phenotype, to have procedures in place to detect the resistance, and to have strategies for managing patients with infections caused by resistant strains.
Literature
1.
Anonymous (2002) Staphylococcus aureus resistant to vancomycin—United States, 2002. Morb Mortal Wkly Rep 51:565–567
2.
Anonymous (2002) Vancomycin-resistant Staphylococcus aureus—Pennsylvania, 2002. Morb Mortal Wkly Rep 51:902
3.
Anonymous (2004) Vancomycin-resistant Staphylococcus aureus—New York, 2004. Morb Mortal Wkly Rep 53:322–323
4.
Ward PB, Johnson PD, Grabsch EA, Mayall BC, Grayson ML (2001) Treatment failure due to methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to vancomycin. Med J Aust 175:480–483
5.
Wootton M, Howe RA, Hillman R, Walsh TR, Bennett PM, MacGowan AP (2001) A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother 47:399–403CrossRef
6.
Howden BP, Ward PB, Charles PG, Korman TM, Fuller A, du Cros P et al (2004) Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 38:521–8
7.
Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML (2004) Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 38:448–451
8.
Kaatz GW, Seo SM, Dorman NJ, Lerner SA (1990) Emergence of teicoplanin resistance during therapy of Staphylococcus aureus endocarditis. J Infect Dis 162:103–108
9.
Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC (1997) Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 40:135–136CrossRefPubMed
10.
Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S et al (1997) Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350:1670–1673CrossRef
11.
Hiramatsu K (2001) Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis 1:147–155
12.
Walsh TR, Howe RA (2002) The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus. Ann Rev Microbiol 56:657–675CrossRef
13.
National Committee for Clinical Laboratory Standards (2004) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A6. NCCLS, Wayne, PA
14.
Tenover FC, Biddle JW, Lancaster MV (2001) Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis 7:327–332
15.
Wootton M, Howe RA, Hillman R, Walsh TR, Bennett PM, MacGowan AP (2001) A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother 47:399–403CrossRef
16.
Sieradzki K, Roberts RB, Haber SW, Tomasz A (1999) The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med 340:517–523CrossRef
17.
Cui L, Ma X, Sato K, Okuma K, Tenover FC, Mamizuka EM et al (2003) Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J Clin Microbiol 41:5–14CrossRef
18.
Hanaki H, Kuwahara-Arai K, Boyle-Vavra S, Daum RS, Labischinski H, Hiramatsu K (1998) Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. J Antimicrob Chemother 42:199–209CrossRef
19.
Sieradzki K, Tomasz A (2003) Alterations of cell wall structure and metabolism accompany reduced susceptibility to vancomycin in an isogenic series of clinical isolates of Staphylococcus aureus. J Bacteriol 185:7103–7110CrossRef
20.
Boyle-Vavra S, Challapalli M, Daum RS (2003) Resistance to autolysis in vancomycin-selected Staphylococcus aureus isolates precedes vancomycin-intermediate resistance. Antimicrob Agents Chemother 47:2036–2039CrossRef
21.
Howe RA, Monk A, Wootton M, Walsh TR, Enright MC (2004) Vancomycin susceptibility within methicillin-resistant Staphylococcus aureus lineages. Emerg Infect Dis 10:855–857
22.
Kuroda M, Kuwahara-Arai K, Hiramatsu K (2000) Identification of the up- and down-regulated genes in vancomycin-resistant Staphylococcus aureus strains Mu3 and Mu50 by cDNA differential hybridization method. Biochem Biophys Res Commun 269:485–490CrossRef
23.
Kuroda M, Kuroda H, Oshima T, Takeuchi F, Mori H, Hiramatsu K (2003) Two-component system VraSR positively modulates the regulation of cell-wall biosynthesis pathway in Staphylococcus aureus. Mol Microbiol 49:807–821CrossRef
24.
Bischoff M, Roos M, Putnik J, Wada A, Glanzmann P, Giachino P et al (2001) Involvement of multiple genetic loci in Staphylococcus aureus teicoplanin resistance. FEMS Microbiol Lett 194:77–82CrossRef
25.
Mongodin E, Finan J, Climo MW, Rosato A, Gill S, Archer GL (2003) Microarray transcription analysis of clinical Staphylococcus aureus isolates resistant to vancomycin. J Bacteriol 185:4638–4643CrossRef
26.
Ike Y, Arakawa Y, Ma X, Tatewaki K, Nagasawa M, Tomita H et al (2001) Nationwide survey shows that methicillin-resistant Staphylococcus aureus strains heterogeneously and intermediately resistant to vancomycin are not disseminated throughout Japanese hospitals. J Clin Microbiol 39:4445–4451CrossRef
27.
Arakawa Y, Ike Y, Nagasawa M (2004) Where has vancomycin-heterogeneously resistant Staphylococcus aureus gone? Lancet 363:1401CrossRef
28.
Hubert SK, Mohammed JM, Fridkin SK, Gaynes RP, McGowan JE Jr, Tenover FC (1999) Glycopeptide-intermediate Staphylococcus aureus: evaluation of a novel screening method and results of a survey of selected U.S. hospitals. J Clin Microbiol 37:3590–3593
29.
Diekema DJ, Pfaller MA, Schmitz FJ, Smayevsky J, Bell J, Jones RN et al (2001) Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY antimicrobial surveillance program, 1997–1999. Clin Infect Dis 32(Suppl 2):S114–S132
30.
Howe RA, Noel AR, Bowker KE, Walsh TR, MacGowan AP (2003) The prevalence of heterogenously vancomycin intermediate Staphylococcus aureus (hVISA) in the USA. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract no. C2-1828
31.
Cartolano GL, Cheron M, Benabid D, Leneveu M, Boisivon A (2004) Methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to glycopeptides (GISA) in 63 French general hospitals. Clin Microbiol Infect 10:448–451
32.
Fridkin SK, Hageman J, McDougal LK, Mohammed J, Jarvis WR, Perl TM et al (2003) Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997–2001. Clin Infect Dis 36:429–439
33.
Walsh TR, Bolmstrom A, Qwarnstrom A, Ho P, Wootton M, Howe RA et al (2001) Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J Clin Microbiol 39:2439–2444CrossRef
34.
Tenover FC, Biddle JW, Lancaster MV (2001) Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis 7:327–332
35.
Wootton M, Avison AB, Bennett PM, Howe RA, Walsh TR (2003) Lack of expression of fmtB/mrp in vancomycin intermediate Staphylococcus aureus (VISA) and hetero (h) VISA phenotype: a new diagnostic marker. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract no. D-1892
36.
Sakoulas G, Eliopoulos GM, Moellering RC Jr, Novick RP, Venkataraman L, Wennersten C et al (2003) Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance? J Infect Dis 187:929–938CrossRef
37.
Moise-Broder PA, Sakoulas G, Eliopoulos GM, Schentag JJ, Forrest A, Moellering RC Jr (2004) Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 38:1700–1705
38.
Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM (2004) Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 42:2398–2402CrossRef
39.
Pavie J, Lefort A, Ploy MC, Massias L, Chau F, Garry L et al (2003) Influence of reduced susceptibility to glycopeptides on activities of vancomycin and teicoplanin against Staphylococcus aureus in experimental endocarditis. Antimicrob Agents Chemother 47:2018–2021CrossRef
40.
Moore MR, Perdreau-Remington F, Chambers HF (2003) Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis. Antimicrob Agents Chemother 47:1262–1266CrossRef
41.
Moise PA, Forrest A, Birmingham MC, Schentag JJ (2002) The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin. J Antimicrob Chemother 50:1017–1026CrossRef
42.
Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B (2002) Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 34:1481–1490
43.
Drew RH, Perfect JR, Srinath L, Kurkimilis E, Dowzicky M, Talbot GH (2000) Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin–dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group. J Antimicrob Chemother 46:775–784CrossRef
44.
Ariza J, Pujol M, Cabo J, Pena C, Fernandez N, Linares J et al (1999) Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. Lancet. 353:1587–1588CrossRef
45.
Schwaber MJ, Wright SB, Carmeli Y, Venkataraman L, DeGirolami PC, Gramatikova A et al (2003) Clinical implications of varying degrees of vancomycin susceptibility in methicillin-resistant Staphylococcus aureus bacteremia. Emerg Infect Dis 9:657–664
Metadata
Title
Low-level vancomycin resistance in Staphylococcus aureus—an Australian perspective
Authors
B. P. Howden
P. B. Ward
P. D. R. Johnson
P. G. P. Charles
M. L. Grayson
Publication date
01-02-2005
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 2/2005
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-004-1261-y

Other articles of this Issue 2/2005

European Journal of Clinical Microbiology & Infectious Diseases 2/2005 Go to the issue

Letter to the Editor

Löfgren’s syndrome: ureaplasmal association questioned

Concise Article

Multidrug-resistant tuberculosis in Russia: clinical characteristics, analysis of second-line drug resistance and development of standardized therapy

Announcements

Februar 2005

Brief Report

Pertussis in adults with persistent cough in South Korea

Article

Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia

Concise Article

Staphylococcus aureus carriage among participants at the 13th European Congress of Clinical Microbiology and Infectious Diseases
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits